Atherosclerosis  ||| S:0 E:16 ||| NNP
and  ||| S:16 E:20 ||| CC
the  ||| S:20 E:24 ||| DT
role  ||| S:24 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
inflammation  ||| S:32 E:45 ||| JJ
Inflammation  ||| S:45 E:58 ||| NNP
plays  ||| S:58 E:64 ||| VBZ
an  ||| S:64 E:67 ||| DT
important  ||| S:67 E:77 ||| JJ
role  ||| S:77 E:82 ||| NN
in  ||| S:82 E:85 ||| IN
the  ||| S:85 E:89 ||| DT
development  ||| S:89 E:101 ||| NN
of  ||| S:101 E:104 ||| IN
atherosclerotic  ||| S:104 E:120 ||| JJ
vascular  ||| S:120 E:129 ||| JJ
disease  ||| S:129 E:137 ||| NN
which  ||| S:137 E:143 ||| WDT
is  ||| S:143 E:146 ||| VBZ
the  ||| S:146 E:150 ||| DT
leading  ||| S:150 E:158 ||| JJ
cause  ||| S:158 E:164 ||| NN
of  ||| S:164 E:167 ||| IN
morbidity  ||| S:167 E:177 ||| NN
and  ||| S:177 E:181 ||| CC
mortality  ||| S:181 E:191 ||| NN
in  ||| S:191 E:194 ||| IN
the  ||| S:194 E:198 ||| DT
adult  ||| S:198 E:204 ||| NN
population ||| S:204 E:214 ||| NN
.  ||| S:214 E:216 ||| .
Various  ||| S:216 E:224 ||| JJ
risk  ||| S:224 E:229 ||| NN
factors  ||| S:229 E:237 ||| NNS
trigger  ||| S:237 E:245 ||| VBP
an  ||| S:245 E:248 ||| DT
inflammatory  ||| S:248 E:261 ||| JJ
response  ||| S:261 E:270 ||| NN
leading  ||| S:270 E:278 ||| VBG
to  ||| S:278 E:281 ||| TO
the  ||| S:281 E:285 ||| DT
initiation  ||| S:285 E:296 ||| NN
and  ||| S:296 E:300 ||| CC
development  ||| S:300 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
atherosclerotic  ||| S:315 E:331 ||| JJ
vascular  ||| S:331 E:340 ||| JJ
disease ||| S:340 E:347 ||| NN
.  ||| S:347 E:349 ||| .
Several  ||| S:349 E:357 ||| JJ
adhesion  ||| S:357 E:366 ||| JJ
molecules ||| S:366 E:375 ||| NNS
,  ||| S:375 E:377 ||| ,
cytokines ||| S:377 E:386 ||| NN
,  ||| S:386 E:388 ||| ,
and  ||| S:388 E:392 ||| CC
growth  ||| S:392 E:399 ||| NN
factors  ||| S:399 E:407 ||| NNS
secreted  ||| S:407 E:416 ||| VBN
from  ||| S:416 E:421 ||| IN
the  ||| S:421 E:425 ||| DT
endothelium  ||| S:425 E:437 ||| JJ
aggravate  ||| S:437 E:447 ||| JJ
inflammation  ||| S:447 E:460 ||| NN
and  ||| S:460 E:464 ||| CC
increase  ||| S:464 E:473 ||| VB
subendothelial  ||| S:473 E:488 ||| JJ
lipid  ||| S:488 E:494 ||| JJ
accumulation ||| S:494 E:506 ||| NN
.  ||| S:506 E:508 ||| .
With  ||| S:508 E:513 ||| IN
continuing  ||| S:513 E:524 ||| VBG
inflammation ||| S:524 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
plaque  ||| S:538 E:545 ||| JJ
rupture  ||| S:545 E:553 ||| NN
occurs  ||| S:553 E:560 ||| VBZ
resulting  ||| S:560 E:570 ||| VBG
in  ||| S:570 E:573 ||| IN
acute  ||| S:573 E:579 ||| JJ
coronary  ||| S:579 E:588 ||| JJ
syndromes ||| S:588 E:597 ||| NN
.  ||| S:597 E:599 ||| .
Recently ||| S:599 E:607 ||| RB
,  ||| S:607 E:609 ||| ,
the  ||| S:609 E:613 ||| DT
importance  ||| S:613 E:624 ||| NN
of  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
immune  ||| S:631 E:638 ||| JJ
system  ||| S:638 E:645 ||| NN
and  ||| S:645 E:649 ||| CC
the  ||| S:649 E:653 ||| DT
mechanisms  ||| S:653 E:664 ||| NNS
of  ||| S:664 E:667 ||| IN
the  ||| S:667 E:671 ||| DT
inflammatory  ||| S:671 E:684 ||| JJ
response  ||| S:684 E:693 ||| NN
have  ||| S:693 E:698 ||| VBP
been  ||| S:698 E:703 ||| VBN
elucidated ||| S:703 E:713 ||| NN
.  ||| S:713 E:715 ||| .
One  ||| S:715 E:719 ||| CD
of  ||| S:719 E:722 ||| IN
the  ||| S:722 E:726 ||| DT
markers  ||| S:726 E:734 ||| NN
of  ||| S:734 E:737 ||| IN
subclinical  ||| S:737 E:749 ||| JJ
inflammation  ||| S:749 E:762 ||| NN
in  ||| S:762 E:765 ||| IN
atherosclerosis  ||| S:765 E:781 ||| NN
is  ||| S:781 E:784 ||| VBZ
increased  ||| S:784 E:794 ||| VBN
levels  ||| S:794 E:801 ||| NNS
of  ||| S:801 E:804 ||| IN
high-sensitivity  ||| S:804 E:821 ||| NNP
CRP ||| S:821 E:824 ||| NNP
.  ||| S:824 E:826 ||| .
Several  ||| S:826 E:834 ||| JJ
clinical  ||| S:834 E:843 ||| JJ
trials  ||| S:843 E:850 ||| NNS
have  ||| S:850 E:855 ||| VBP
shown  ||| S:855 E:861 ||| VBN
that  ||| S:861 E:866 ||| IN
suppression  ||| S:866 E:878 ||| NN
of  ||| S:878 E:881 ||| IN
the  ||| S:881 E:885 ||| DT
inflammatory  ||| S:885 E:898 ||| JJ
response  ||| S:898 E:907 ||| NN
can  ||| S:907 E:911 ||| MD
delay  ||| S:911 E:917 ||| VB
or  ||| S:917 E:920 ||| CC
decrease  ||| S:920 E:929 ||| VB
the  ||| S:929 E:933 ||| DT
atherosclerotic  ||| S:933 E:949 ||| JJ
process ||| S:949 E:956 ||| NN
.  ||| S:956 E:958 ||| .
Among  ||| S:958 E:964 ||| IN
the  ||| S:964 E:968 ||| DT
approaches  ||| S:968 E:979 ||| NNS
for  ||| S:979 E:983 ||| IN
a  ||| S:983 E:985 ||| DT
healthier  ||| S:985 E:995 ||| JJ
lifestyle ||| S:995 E:1004 ||| NN
,  ||| S:1004 E:1006 ||| ,
diets  ||| S:1006 E:1012 ||| JJ
low  ||| S:1012 E:1016 ||| JJ
in  ||| S:1016 E:1019 ||| IN
saturated  ||| S:1019 E:1029 ||| JJ
fats ||| S:1029 E:1033 ||| NNS
,  ||| S:1033 E:1035 ||| ,
the  ||| S:1035 E:1039 ||| DT
Mediterranean  ||| S:1039 E:1053 ||| NNP
diet ||| S:1053 E:1057 ||| NN
,  ||| S:1057 E:1059 ||| ,
and  ||| S:1059 E:1063 ||| CC
exercise  ||| S:1063 E:1072 ||| NN
have  ||| S:1072 E:1077 ||| VBP
been  ||| S:1077 E:1082 ||| VBN
shown  ||| S:1082 E:1088 ||| VBN
to  ||| S:1088 E:1091 ||| TO
decrease  ||| S:1091 E:1100 ||| VB
the  ||| S:1100 E:1104 ||| DT
inflammatory  ||| S:1104 E:1117 ||| JJ
response ||| S:1117 E:1125 ||| NN
.  ||| S:1125 E:1127 ||| .
Various  ||| S:1127 E:1135 ||| JJ
pharmacologic  ||| S:1135 E:1149 ||| JJ
agents  ||| S:1149 E:1156 ||| NNS
also  ||| S:1156 E:1161 ||| RB
have  ||| S:1161 E:1166 ||| VB
anti-inflammatory  ||| S:1166 E:1184 ||| JJ
effects ||| S:1184 E:1191 ||| NNS
.  ||| S:1191 E:1193 ||| .
Lipid-lowering  ||| S:1193 E:1208 ||| JJ
therapies ||| S:1208 E:1217 ||| NNS
,  ||| S:1217 E:1219 ||| ,
in  ||| S:1219 E:1222 ||| IN
particular  ||| S:1222 E:1233 ||| JJ
statins  ||| S:1233 E:1241 ||| NNS
have  ||| S:1241 E:1246 ||| VBP
proved  ||| S:1246 E:1253 ||| VBN
to  ||| S:1253 E:1256 ||| TO
have  ||| S:1256 E:1261 ||| VB
anti-inflammatory  ||| S:1261 E:1279 ||| JJ
effects  ||| S:1279 E:1287 ||| NNS
on  ||| S:1287 E:1290 ||| IN
atheromatous  ||| S:1290 E:1303 ||| JJ
plaques ||| S:1303 E:1310 ||| NN
.  ||| S:1310 E:1312 ||| .
Several  ||| S:1312 E:1320 ||| JJ
clinical  ||| S:1320 E:1329 ||| JJ
trials  ||| S:1329 E:1336 ||| NNS
have  ||| S:1336 E:1341 ||| VBP
shown  ||| S:1341 E:1347 ||| VBN
that  ||| S:1347 E:1352 ||| IN
patients  ||| S:1352 E:1361 ||| NNS
with  ||| S:1361 E:1366 ||| IN
an  ||| S:1366 E:1369 ||| DT
increased  ||| S:1369 E:1379 ||| JJ
inflammatory  ||| S:1379 E:1392 ||| JJ
response  ||| S:1392 E:1401 ||| NN
benefit  ||| S:1401 E:1409 ||| NN
more  ||| S:1409 E:1414 ||| RBR
from  ||| S:1414 E:1419 ||| IN
statins ||| S:1419 E:1426 ||| NN
.  ||| S:1426 E:1428 ||| .
Therapeutic  ||| S:1428 E:1440 ||| JJ
approaches  ||| S:1440 E:1451 ||| NNS
targeting  ||| S:1451 E:1461 ||| VBG
directly  ||| S:1461 E:1470 ||| RB
the  ||| S:1470 E:1474 ||| DT
inflammatory  ||| S:1474 E:1487 ||| JJ
response  ||| S:1487 E:1496 ||| NN
and  ||| S:1496 E:1500 ||| CC
vaccination  ||| S:1500 E:1512 ||| NN
against  ||| S:1512 E:1520 ||| IN
atherosclerosis  ||| S:1520 E:1536 ||| NNS
are  ||| S:1536 E:1540 ||| VBP
under  ||| S:1540 E:1546 ||| IN
investigation ||| S:1546 E:1559 ||| NN
.  ||| S:1559 E:1561 ||| .
